(17078830), Q. X., (17078833), K. H., (17078836), X. M., (17078839), Y. W., (17078842), L. Z., (17078845), L. B., . . . (17078857), Q. C. (2025). Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
Chicago Style (17th ed.) Citation(17078830), Qingsheng Xu, et al. Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. 2025.
MLA citiranje(17078830), Qingsheng Xu, et al. Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. 2025.
Opozorilo: Ti citati niso vedno 100% točni.